Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended September 30 - Earnings Summary
17/12/2024 14:27
* Sonnet Biotherapeutics Holdings Inc SONN.OQ reported a
quarterly adjusted loss of $3.83 per share for the quarter
ended September 30, higher than the same quarter last year, when
the company reported EPS of $-16.72. The lone analyst forecast
for the quarter was for a loss of $5.52 per share.
* Reported revenue was zero; analysts expected zero.
* Sonnet Biotherapeutics Holdings Inc's reported EPS for the
quarter was a loss of $3.83.
* The company reported a quarterly loss of $3.13 million.
* Sonnet Biotherapeutics Holdings Inc shares had fallen
by 72.9%
this quarter and lost 87.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 9.5%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Sonnet
Biotherapeutics Holdings Inc is $240.00
This summary was machine generated from LSEG data December 17 at
02:26 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -5.52 -3.83 Beat
Jun. 30 2024 -6.12 -5.60 Beat
Mar. 31 2024 1.08 0.56 Missed
Dec. 31 2023 -7.20 -2.48 Beat